TCRT

Alaunos Therapeutics, Inc. (TCRT) - 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Alaunos Therapeutics, Inc. is a pre-clinical stage biopharmaceutical company focused on developing oral small molecules for obesity and metabolic disorders, specifically the candidate ALN1003. The Company has historically developed TCR-T therapies but has reprioritized to its obesity program. As of June 30, 2026, the Company had 2,486,140 shares of common stock outstanding.

Key Financial Metrics

Liquidity: As of June 30, 2026, the Company held approximately $0.12 million in cash. Management estimates a monthly cash burn rate of approximately $0.21 million, with resources sufficient to fund operations only into the third quarter of 2026.

Material Changes vs. Prior Period

• Revenue: Revenue was $0 for the six months ended June 30, 2026, compared to $2,000 in the prior year period. The Company has no recurring revenue from operations.
• Operating Expenses:
  • Research and Development (R&D): Increased by 53% to $814,000 (from $531,000), driven by increased stock-based compensation, salaries, and consulting fees for the obesity program.
  • General and Administrative (G&A): Decreased by 28% to $1,150,000 (from $1,603,000), attributed to downsized operations and reduced costs in salaries, insurance, legal, and travel.
• Cash Position: Cash decreased by $1.26 million during the period, primarily due to operating losses. Financing activities provided only $70,000 via an equity line of credit, compared to $3.26 million in equity raises in the prior year.
• Equity: Stockholders' equity declined to $652,000, falling below the Nasdaq minimum requirement of $2.5 million.

Outlook, Risks, and Management Commentary

Going Concern: Management has raised substantial doubt about the Company's ability to continue as a going concern. The Company requires substantial additional capital to fund planned operations and advance the ALN1003 program. If funding is not secured, the Company may curtail operations or pursue dissolution.

Nasdaq Listing Status:

• Stockholders' Equity Deficiency: The Company received a notice from Nasdaq on April 9, 2026, regarding non-compliance with the $2.5 million minimum stockholders' equity requirement. A plan to regain compliance has been submitted.
• Market Value of Listed Securities (MVLS): A new Nasdaq rule requiring a $5.0 million MVLS was approved but is currently stayed pending SEC review. If implemented and the Company fails to comply, it could face immediate delisting without a cure period.

Program Progress (ALN1003): Recent preclinical studies in diet-induced obesity (DIO) mouse models showed statistically significant dose-related reductions in body weight, improvements in body composition (fat loss with lean mass preservation), and favorable metabolic biomarkers (insulin resistance, liver function). The Company plans to conduct additional preclinical studies and IND-enabling activities subject to capital availability.

Internal Controls: The Company identified a material weakness in internal controls over financial reporting, concluding that disclosure controls and procedures were not effective as of June 30, 2026.

Investor Verification Checklist

• Cash Runway: Verify the accuracy of the projected cash runway into Q3 2026 and the immediate need for capital raises.
• Nasdaq Compliance: Monitor the status of the plan to regain compliance with the $2.5 million stockholders' equity requirement and the potential impact of the stayed $5.0 million MVLS rule.
• Capital Raising: Assess the likelihood and terms of securing additional financing, given the lack of committed capital sources.
• Preclinical Data: Review the detailed statistical analysis of the ALN1003 DIO studies to validate the proof-of-concept claims regarding metabolic effects.
• Internal Controls: Evaluate the remediation plan for the identified material weakness in internal controls over financial reporting.